Recce Pharmaceuticals (RCE) Investor Presentation summary

Business overview and strategy

• Developing a new class of synthetic anti-infectives targeting antibiotic-resistant superbugs, with lead candidate RECCE® 327 recognized by WHO as a clinically advanced new antibiotic class.

• Multiple Phase II/III clinical trials underway in key geographies, with a registrational Phase III trial in Indonesia as a catalyst for 2026 revenues.

• Strategic MoU with PT Etana Biotechnologies to facilitate late-stage clinical trials and commercial access in Indonesia and ASEAN.

• Expedited regulatory review in Indonesia and support from both Australian and Indonesian governments for regional expansion.

• Global growth strategy includes expansion into ASEAN, Australia/NZ, USA, and new product indications.

Product pipeline and clinical progress

• Lead asset RECCE® 327 Gel in Phase III for diabetic foot infections (DFI) in Indonesia, with expected launch in 2026 and access to ASEAN markets.

• Broad pipeline includes indications for sepsis, UTI/urosepsis, burn wounds, and ABSSSI, with multiple formulations (IV, topical, aerosol).

• Phase II DFI/ABSSSI trial achieved all endpoints, with 93% efficacy at 14 days and no serious adverse events.

• US Department of Defense grant supports burn wound infection program; IND application to FDA planned.

• Phase III registration trial in Indonesia is a double-blind, placebo-controlled study with interim analysis planned for early 2026.

Market opportunity

• Global DFI and sepsis markets exceed US$9.1 billion, with initial focus on Indonesia (DFI market ~US$189 million) and broader Asia Pacific (~US$1 billion/year).

• US and Australian markets for sepsis and DFI worth over US$1.5 billion.

• Additional opportunities in burn wound, skin, and soft tissue infections.